>

Asclepii

Turning a $30K regenerative therapy into $300
Cleveland

About Asclepii

What is Asclepii? – Asclepii is a company reinventing the future of tissue engineering, starting with our product called Artemis

What is Artemis? – Artemis is an innovative extracellular matrix (ECM) that has a pre-integrated proprietary growth factor that creates unprecedented levels of cellular adhesion, cellular kinetics, and coagulation in mere minutes. This discovery also allows integration of therapeutics directly into the Artemis matrix

How Does it Work? – Artemis is a shelf-stable, durable extracellular matrix (ECM) that can be placed on any damage of the skin: whether it be acute/chronic, burn, ulcer, impact injury, or incision. This allows Artemis to be used for wound care in almost any setting for almost any indication where wound healing or tissue regeneration would be beneficial, at minimal cost to the patient

Tagged with

Team

Problem statement

Cell therapy is the future of human health, with the potential to address underlying causes of disease, reduce the severity of illness, and reduce healthcare utilization. However, current cell therapies have high upfront costs and operating expenses, requiring complex and hard-to-scale infrastructure to execute, severely limiting their accessibility and potential and costing from $30–45K USD per treatment on average. The centerpiece of regenerative therapies (including but not limited to hematopoietic, myocardial, neural, and skeletal repair therapies) is the scaffold, which acts as the growth-inducing environment for cells. However, current scaffolds such as decellularized fish skin (Kerecis, acq. US$1.3 B Jul 2023) or bovine intestines (Healthpoint, acq. US$780MM 2012) are highly complex, application-specific, and costly. There is a pressing need for novel, more cost-effective, and versatile scaffolds capable of creating more accessible and effective cell therapies.

Traction information

Over US$1 MM raised in non-dilutive funding
R&D Partnerships in 7 countries
22.000 sq ft manufacturing plant commitment
2024 SXSW Pitch Finalist
2024 Hult Prize Summit Finalist
2024 Morgenthaler-Pavey Startup Competition Science Track Winner

Product images

Updates

Bella Taylor has visited this profile using a private link.
Added 4 months ago
Sammie Irwin has visited this profile using a private link.
Added 4 months ago
Anish Zute has visited this profile using a private link.
Added 4 months ago
Anish has visited this profile using a private link.
Added 4 months ago
Kathryn Moore has visited this profile using a private link.
Added 4 months ago
Kathryn Moore has visited this profile using a private link.
Added 4 months ago
Talha Khan has visited this profile using a private link.
Added 4 months ago
francesco cassinerio has visited this profile using a private link.
Added 4 months ago
Drew Rice has visited this profile using a private link.
Added 4 months ago
Morgan Odell has visited this profile using a private link.
Added 4 months ago

Funding

Currently raising capital

$400,000
committed
$3,500,000
round goal
Total raised to date:$1,083,000

Pitch deck

Network

Pitch is a Capital Factory product. © Capital Factory 2024. Privacy policy.